Use of protein repair therapy in the treatment of cystic fibrosis

Ronald C. Rubenstein, Pamela L. Zeitlin

Research output: Contribution to journalArticle

Abstract

Disruption in the biosynthesis or function the cystic fibrosis transmembrane conductance regulator (CFTR) results from over 700 different mutations in the CFTR gene. It is useful to classify these mutations by the nature of the resulting defect. Understanding the molecular mechanism that leads to CFTR dysfunction stimulates the design of therapeutic strategies based on restoration of CFTR function to the mutant protein, or 'protein repair therapy.' This review links the classification of CFTR mutations to a number of new pharmacologic strategies that lead to enhancement of CFTR function by manipulation of mutant CFTR.

Original languageEnglish (US)
Pages (from-to)250-255
Number of pages6
JournalCurrent Opinion in Pediatrics
Volume10
Issue number3
DOIs
StatePublished - 1998

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Cystic Fibrosis
Proteins
Mutation
Therapeutics
Mutant Proteins
Regulator Genes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Use of protein repair therapy in the treatment of cystic fibrosis. / Rubenstein, Ronald C.; Zeitlin, Pamela L.

In: Current Opinion in Pediatrics, Vol. 10, No. 3, 1998, p. 250-255.

Research output: Contribution to journalArticle

Rubenstein, Ronald C. ; Zeitlin, Pamela L. / Use of protein repair therapy in the treatment of cystic fibrosis. In: Current Opinion in Pediatrics. 1998 ; Vol. 10, No. 3. pp. 250-255.
@article{ca53a457b8a54e37bc4574d4440ac02a,
title = "Use of protein repair therapy in the treatment of cystic fibrosis",
abstract = "Disruption in the biosynthesis or function the cystic fibrosis transmembrane conductance regulator (CFTR) results from over 700 different mutations in the CFTR gene. It is useful to classify these mutations by the nature of the resulting defect. Understanding the molecular mechanism that leads to CFTR dysfunction stimulates the design of therapeutic strategies based on restoration of CFTR function to the mutant protein, or 'protein repair therapy.' This review links the classification of CFTR mutations to a number of new pharmacologic strategies that lead to enhancement of CFTR function by manipulation of mutant CFTR.",
author = "Rubenstein, {Ronald C.} and Zeitlin, {Pamela L.}",
year = "1998",
doi = "10.1097/00008480-199806000-00005",
language = "English (US)",
volume = "10",
pages = "250--255",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Use of protein repair therapy in the treatment of cystic fibrosis

AU - Rubenstein, Ronald C.

AU - Zeitlin, Pamela L.

PY - 1998

Y1 - 1998

N2 - Disruption in the biosynthesis or function the cystic fibrosis transmembrane conductance regulator (CFTR) results from over 700 different mutations in the CFTR gene. It is useful to classify these mutations by the nature of the resulting defect. Understanding the molecular mechanism that leads to CFTR dysfunction stimulates the design of therapeutic strategies based on restoration of CFTR function to the mutant protein, or 'protein repair therapy.' This review links the classification of CFTR mutations to a number of new pharmacologic strategies that lead to enhancement of CFTR function by manipulation of mutant CFTR.

AB - Disruption in the biosynthesis or function the cystic fibrosis transmembrane conductance regulator (CFTR) results from over 700 different mutations in the CFTR gene. It is useful to classify these mutations by the nature of the resulting defect. Understanding the molecular mechanism that leads to CFTR dysfunction stimulates the design of therapeutic strategies based on restoration of CFTR function to the mutant protein, or 'protein repair therapy.' This review links the classification of CFTR mutations to a number of new pharmacologic strategies that lead to enhancement of CFTR function by manipulation of mutant CFTR.

UR - http://www.scopus.com/inward/record.url?scp=0031710543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031710543&partnerID=8YFLogxK

U2 - 10.1097/00008480-199806000-00005

DO - 10.1097/00008480-199806000-00005

M3 - Article

VL - 10

SP - 250

EP - 255

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 3

ER -